Novartis
Highly Engaged Employees
Manufacturing · Switzerland · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Lichtstrasse 35, Basel, Basel-City, 4056...Phone Number
+41 613241111Website
www.novartis.comRevenue
$56.7 BillionStock Symbol
NVSIndustry
About Novartis
Novartis Org Chart
Is Novartis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Novartis is spiking on competitors!
Check if Novartis has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Novartis
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Novartis has new funding data
Click to see if Novartis had a recent Job posting/layoffs
Novartis, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Novartis launches new products
Earning: See what the market has to say on Novartis recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Novartis
Compare insights from companies similar to Novartis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Novartis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Novartis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Novartis.
Novartis Tech Stack
A closer look at the technologies used by Novartis
Most Recent Scoops
Novartis News & Media
European Commission approves Novartis’ Itvisma to treat SMA
The approval is supported by data from the STEER, Phase IIIb STRENGTH and Phase I/II STRONG studies.Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Basel, June 30, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene.Novartis Eyes $5 Billion Pluvicto Opportunity
Radioligand therapy market could grow from $3.2 billion in 2025 to $30 billion by 2034.Novartis targets undruggable cancers with $1.9bn Antares Therapeutics deal
Antares’ lead precision oncology programme is expected to enter the clinic in 2026.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novartis
Novartis is a global pharmaceutical manufacturer headquartered in Switzerland, specializing in developing and producing innovative medications and healthcare solutions. The company focuses on research and development of treatments across multiple therapeutic areas to address various medical conditions and improve patient outcomes worldwide. Novarti... Read More